More Stories
Regeneron’s stock dips after earnings fall short of estimates
Regeneron Pharmaceuticals’ stock fell 2.6% premarket Thursday, after the drug company’s first-quarter profit and revenue fell short of analyst estimates.
We’re all paying a high price for letting corporations have free rein over us
Deliberately weakening social protections has created greater financial and economic insecurity.
Intel and Microsoft are on different paths to profit from AI. One will be right.
Tech giants’ recent earnings reveal a clear winner in market leadership and momentum.
Novartis to pay up to $1.75 billion for U.S. cancer-focused biotech
Novartis on Thursday said it will pay up to $1.75 billion for a U.S. biotech focused on cancer.
What if you could take your existing mortgage with you to a new house?
Here’s the key that could unlock the U.S. housing market for buyers and sellers.
My grandmother’s house was split between her 10 kids almost 50 years ago. How do we figure out the cost basis?
If the property has been held for a long time things can become complicated.